A Phase 3 interventional study of Test Article A and Test Article B in Progressive Keratoconus, sponsored by Glaukos Corporation. Completed at 1 site in United States. Open to participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-01-30.
Sponsored by Glaukos Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Keratoconus with a site in United States — 27 open to participants now, 33 under way, 9 of them phase 3. Keratoconus · United States.
Among the 94 studies in Keratoconus with a site in United States, this one is the 25th largest by enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2018, is one of 23 in phase 3, and was the 50th registered.
313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.
Browse Keratoconus studies →27 of the 94 studies in Keratoconus with a site in United States are open now. Recruiting first, the newest first:
Alcon Research · Sites in United States
Ages 22+ · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 20–79 · Healthy volunteers
Glaukos Corporation · Sites in United States
Ages 13+
Glaukos Corporation · Sites in United States
Ages 18–55
Price Vision Group · Sites in United States
Ages 10–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 12 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 22 · Phase 3 29 · Phase 4 4
First in 1995; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 40 across 205 interventional studies indexed under Keratoconus.
Median enrollment 147 across the 71 interventional studies, 168 across the 21 observational. Of the 43 that completed or were terminated, 15 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 94 have an industry lead sponsor. The 10 most frequent:
Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
Glaukos Corporation has 9 studies filed under Keratoconus — fewer than ten, so there is no comparison to draw.
9 of the studies in Keratoconus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06235567Maanasa Indaram, MDDextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking | 2026-12 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-12 |
| NCT03760432Oregon Health and Science UniversityCollagen Cross-linking in Keratoconus | 2026-12 |
| NCT07400952Glaukos CorporationPlacebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus | 2027-04 |
| NCT03030755The Cleveland ClinicCorneal Elastography and Patient Specific Modeling | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 94 studies in Keratoconus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus. Epithelium-on CXL uses a formulation that allows the riboflavin to penetrate the cornea without the need to remove the epithelium, the outer most layer of the cornea.
Up to 275 study eyes with progressive keratoconus will be enrolled. Study eyes will be randomized in a 2:1 ratio to receive CXL treatment or sham/control treatment.The primary efficacy endpoint is a difference of ≥ 1 diopter between treatment groups in the mean change in Kmax from baseline to Month 6.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study eye receives Test Article A, Test Article B, and exposed to cross-linking dose of UVA light generated by the KXL medical device system
Drug: Test Article A · Drug: Test Article B · Device: KXL medical device system
Sham eye receives Placebo and and exposed to mock dose of UVA light generated by the KXL medical device system
Drug: Placebo · Device: KXL medical device system
Riboflavin Ophthalmic Solution A
Riboflavin Ophthalmic Solution B
Placebo Vehicle of Test Article
Mock UVA light source
Cross-linking UVA light source
Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax
Mean difference of at least 1 diopter in Kmax change from baseline to Month 6 between treatment groups
Time frame: 6 months
Difference Between Treatment Groups in the Change From Baseline to Month 12 in Kmax
Difference between the CXL and Sham/Control treatment groups in the change from baseline to Month 12 in Kmax
Time frame: 12 months
Subjects were recruited at eye clinics and were required to meet inclusion/exclusion criteria prior to enrollment
| Milestone | Epithelium-on CXL Treatment Group | Sham Treatment/Control Group |
|---|---|---|
| Started | 156 | 83 |
| Month 6 | 153 | 82 |
| Month 12 | 150 | 0 |
| Completed | 150 | 82 |
| Not completed | 6 | 1 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 |
Mean difference of at least 1 diopter in Kmax change from baseline to Month 6 between treatment groups
| Diopters | Epithelium-on CXL Treatment Group | Sham Treatment/Control Group |
|---|---|---|
| Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax | -0.3 (-0.6 to -0.0) | 0.6 (0.2 to 1.1) |
Difference between the CXL and Sham/Control treatment groups in the change from baseline to Month 12 in Kmax
| Diopters | Epithelium-on CXL Treatment Group | Sham Treatment/Control Group |
|---|---|---|
| Difference Between Treatment Groups in the Change From Baseline to Month 12 in Kmax | -0.4 (-0.7 to -0.2) | 0.7 (0.3 to 1.1) |
Collected over 12 months for the Epithelium-on CXL Treatment Group and 6 months for the Sham Treatment/Control Group. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ocular: Epithelium-on CXL Treatment Group | 0/189 (0%) | 1/189 (0.5%) | 170/189 (89.9%) |
| Ocular: Sham Treatment/Control Group | 0/90 (0%) | 0/90 (0%) | 63/90 (70%) |
| Non-ocular: Epithelium-on | 0/118 (0%) | 2/118 (1.7%) | 1/118 (0.8%) |
| Non-ocular: Sham Treatment/Control | 0/45 (0%) | 0/45 (0%) | 0/45 (0%) |
| Non-ocular: Epithelium-on and Sham Treatment | 0/38 (0%) | 1/38 (2.6%) | 2/38 (5.3%) |
| Event | Ocular: Epithelium-on CXL Treatment Group | Ocular: Sham Treatment/Control Group | Non-ocular: Epithelium-on | Non-ocular: Sham Treatment/Control | Non-ocular: Epithelium-on and Sham Treatment |
|---|---|---|---|---|---|
| Uterine leiomyomaReproductive system and breast disorders | 0/189 | 0/90 | 0/118 | 0/45 | 1/38 |
| Urinary tract infectionRenal and urinary disorders | — | — | 1/118 | 0/45 | 0/38 |
| Kidney infectionRenal and urinary disorders | — | 0/90 | 1/118 | 0/45 | 0/38 |
| Depression suicidalPsychiatric disorders | 0/189 | 0/90 | 1/118 | 0/45 | 0/38 |
| Cataract subcapsularEye disorders | 1/189 | 0/90 | 0/118 | 0/45 | 0/38 |
| Retinal detachmentEye disorders | 1/189 | 0/90 | 0/118 | 0/45 | 0/38 |
| Corneal opacityEye disorders | 1/189 | 0/90 | 0/118 | 0/45 | 0/38 |
| Event | Ocular: Epithelium-on CXL Treatment Group | Ocular: Sham Treatment/Control Group | Non-ocular: Epithelium-on | Non-ocular: Sham Treatment/Control | Non-ocular: Epithelium-on and Sham Treatment |
|---|---|---|---|---|---|
| Conjunctival hyperaemiaEye disorders | 115/189 | 25/90 | 0/118 | 0/45 | 0/38 |
| Corneal opacityEye disorders | 77/189 | 11/90 | 0/118 | 0/45 | 0/38 |
| PhotophobiaEye disorders | 73/189 | 12/90 | 0/118 | 0/45 | 0/38 |
| Punctate keratitisEye disorders | 66/189 | 27/90 | 0/118 | 0/45 | 0/38 |
| Eye painEye disorders | 61/189 | 5/90 | 0/118 | 0/45 | 0/38 |
| Eye irritationEye disorders | 59/189 | 7/90 | 0/118 | 0/45 | 0/38 |
| Lacrimation increasedEye disorders | 36/189 | 1/90 | 0/118 | 0/45 | 0/38 |
| Corneal epithelium defectEye disorders | 28/189 | 0/90 | 0/118 | 0/45 | 0/38 |
| Eyelid oedemaEye disorders | 27/189 | 2/90 | 0/118 | 0/45 | 0/38 |
| Corneal striaeEye disorders | 26/189 | 4/90 | 0/118 | 0/45 | 0/38 |
Subjects with progressive keratoconus in at least one eye (study eye). Subjects may contribute more than one eye if both eyes qualify. Eyes vs. subjects were randomized to the treatment arms.
| Age, Continuous(years) | Epithelium-on CXL Treatment Group | Sham Treatment/Control Group | Total |
|---|---|---|---|
| Mean | 30.0 ± 9.75 | 29.5 ± 9.67 | 30.0 ± 9.9 |
| Sex/Gender, Customized(participants) | Epithelium-on CXL Treatment Group | Sham Treatment/Control Group | Total |
|---|---|---|---|
| Male | 109 | 55 | 139 |
| Female | 47 | 28 | 62 |
| Race/Ethnicity, Customized(participants) | Epithelium-on CXL Treatment Group | Sham Treatment/Control Group | Total |
|---|---|---|---|
| Ethnicity: Hispanic or Latino | 28 | 68 | 36 |
| Ethnicity: Not Hispanic or Latino | 128 | 15 | 165 |
| Race/Ethnicity, Customized(participants) | Epithelium-on CXL Treatment Group | Sham Treatment/Control Group | Total |
|---|---|---|---|
| Race: Asian | 3 | 4 | 5 |
| Race: Black or African American | 27 | 18 | 36 |
| Race: Native Hawaiian or Other Pacific Islander | 3 | 1 | 3 |
| Race: White | 112 | 54 | 142 |
| Race: Other | 11 | 6 | 15 |
| Mean Kmax (D)(Diopters) | Epithelium-on CXL Treatment Group | Sham Treatment/Control Group | Total |
|---|---|---|---|
| Mean | 59.4 ± 9.1 | 59.3 ± 9.1 | 59.4 ± 9.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Nov 2019, 18 months.
Results were first posted in Jan 2024, 4 years 2 months after primary completion. A results delay was requested in Dec 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.